Even the solid proposals set out by the Trump administration are being undermined by its actions taken elsewhere.

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

The agency and Novo Nordisk, which makes Ozempic, said Monday that they had learned about "several hundred units" of the drug ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

President Trump directed his administration to help states import drugs from Canada. But a proposal to alter a Medicare ...